Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,291
  • Shares Outstanding, K 36,239
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,260 K
  • EBIT $ -151 M
  • EBITDA $ -150 M
  • 60-Month Beta -0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.95

Options Overview Details

View History
  • Implied Volatility 179.27% ( +3.89%)
  • Historical Volatility 103.37%
  • IV Percentile 86%
  • IV Rank 54.52%
  • IV High 290.82% on 12/09/24
  • IV Low 45.55% on 06/06/24
  • Put/Call Vol Ratio 3.03
  • Today's Volume 1,930
  • Volume Avg (30-Day) 2,846
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 113,429
  • Open Int (30-Day) 104,096

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.00
  • Number of Estimates 5
  • High Estimate -0.86
  • Low Estimate -1.20
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -2.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +11.02%
on 12/18/24
7.50 -43.60%
on 11/26/24
-2.05 (-32.64%)
since 11/20/24
3-Month
3.81 +11.02%
on 12/18/24
13.07 -67.64%
on 10/09/24
-4.41 (-51.04%)
since 09/20/24
52-Week
3.61 +17.17%
on 06/07/24
20.21 -79.07%
on 02/01/24
-9.52 (-69.24%)
since 12/20/23

Most Recent Stories

More News
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

BMEA : 4.23 (+3.68%)
Biomea Fusion to Host Conference Call Presenting Topline Results from Phase II Trial of Icovamenib in Type 2 Diabetes

Biomea Fusion will discuss COVALENT-111 Phase II trial results for icovamenib in type 2 diabetes on December 17, 2024.Quiver AI SummaryBiomea Fusion, Inc. announced that it will host a conference call...

BMEA : 4.23 (+3.68%)
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

BMEA : 4.23 (+3.68%)
Biomea Fusion Announces Promising Preclinical Results for Icovamenib in Enhancing Beta Cell Function and Synergy with GLP-1-Based Therapies

Icovamenib improves beta cell function and insulin secretion, enhancing effectiveness of GLP-1 therapies in diabetes treatment.Quiver AI SummaryBiomea Fusion, Inc. announced positive results from preclinical...

BMEA : 4.23 (+3.68%)
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

BMEA : 4.23 (+3.68%)
Biomea Fusion, Inc. Announces Promising Preliminary Phase I Data for BMF-500 in Treating Relapsed or Refractory Acute Leukemia with FLT3 Mutations

Preliminary data indicates BMF-500 may effectively treat R/R acute leukemia with FLT3 mutations, showing promising safety and efficacy.Quiver AI SummaryBiomea Fusion, Inc. has announced promising preliminary...

BMEA : 4.23 (+3.68%)
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

BMEA : 4.23 (+3.68%)
Biomea Fusion to Present Data from Phase I Trial of BMF-500 for Acute Leukemia on December 9, 2024

Biomea Fusion announces a conference call to present Phase I trial data for BMF-500 in acute leukemia on December 9, 2024.Quiver AI SummaryBiomea Fusion, Inc., a biopharmaceutical company focused on developing...

BMEA : 4.23 (+3.68%)
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

BMEA : 4.23 (+3.68%)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BMEA : 4.23 (+3.68%)

Business Summary

Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion Inc. is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 4.67
2nd Resistance Point 4.48
1st Resistance Point 4.35
Last Price 4.23
1st Support Level 4.03
2nd Support Level 3.84
3rd Support Level 3.71

See More

52-Week High 20.21
Fibonacci 61.8% 13.87
Fibonacci 50% 11.91
Fibonacci 38.2% 9.95
Last Price 4.23
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar